4.7 Article

The KEAP1-NRF2 pathway: Targets for therapy and role in cancer

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Review Pharmacology & Pharmacy

Advances and challenges in therapeutic targeting of NRF2

Albena T. Dinkova-Kostova et al.

Summary: Activation of NRF2 has the potential to address oxidative stress, inflammation, and metabolic imbalances in chronic pathologies. This article discusses the rationale for targeting NRF2, recent advances in drug development of NRF2 modulators, and the challenges in fully harnessing NRF2 as a therapeutic target.

TRENDS IN PHARMACOLOGICAL SCIENCES (2023)

Article Biochemistry & Molecular Biology

Design and characterization of a heterobifunctional degrader of KEAP1

Hao Chen et al.

Summary: A proteolysis targeting chimera (PROTAC) that depletes KEAP1 and activates the NRF2 antioxidant response has been developed as a potential strategy to treat diseases caused by oxidative stress. The optimized PROTAC 14 demonstrated potent KEAP1 degradation and increased expression of antioxidant proteins, effectively preventing cell death induced by reactive oxygen species. This approach presents an alternative therapeutic strategy for oxidative stress-related diseases.

REDOX BIOLOGY (2023)

Article Biochemistry & Molecular Biology

A pan-cancer analysis shows immunoevasive characteristics in NRF2 hyperactive squamous malignancies

Jouni Harkonen et al.

Summary: The NRF2 pathway is frequently activated in various cancer types, but a comprehensive analysis of its effects across different malignancies is currently lacking. We developed a NRF2 activity metric and conducted a pan-cancer analysis of oncogenic NRF2 signaling using it. Our findings revealed an immunoevasive phenotype in squamous malignancies of the lung, head and neck area, cervix, and esophagus, where high NRF2 activity is associated with low interferon-gamma (IFNγ), HLA-I expression, and T cell and macrophage infiltration. These tumors have a molecular phenotype with amplification of SOX2/TP63, TP53 mutation, and CDKN2A loss, and are associated with upregulation of immunomodulatory genes NAMPT, WNT5A, SPP1, SLC7A11, SLC2A1, and PD-L1. Our functional genomics analyses suggest that these genes are candidate NRF2 targets, indicating a direct modulation of the tumor immune milieu. Single-cell mRNA data shows that cancer cells of this subtype exhibit decreased expression of IFNγ responsive ligands and increased expression of immunosuppressive ligands NAMPT, SPP1, and WNT5A involved in intercellular crosstalk. Moreover, the negative relationship between NRF2 and immune cells is explained by stromal populations of lung squamous cell carcinoma, indicating a potential effect across multiple squamous malignancies based on our molecular subtyping and deconvolution data.

REDOX BIOLOGY (2023)

Article Biochemistry & Molecular Biology

EMSY inhibits homologous recombination repair and the interferon response, promoting lung cancer immune evasion

Antonio Marzio et al.

Summary: NSCLCs with KEAP1 mutations show resistance to immunotherapy due to EMSY accumulation suppressing immune response. KEAP1 loss results in stabilized EMSY, causing HRR defects and sensitivity to PARP inhibitors. The accumulation of EMSY impairs immune signaling and promotes immune evasion. Activation of the type I interferon response using a STING agonist inhibits KEAP1-mutant tumor growth, suggesting a potential therapeutic strategy for NSCLC patients with KEAP1 alterations.
Article Oncology

Mutational Activation of the NRF2 Pathway Upregulates Kynureninase Resulting in Tumor Immunosuppression and Poor Outcome in Lung Adenocarcinoma

Johannes F. Fahrmann et al.

Summary: Activation of the NRF2 pathway can lead to upregulation of KYNU in lung cancer, which is associated with tumor immunosuppression.

CANCERS (2022)

Article Multidisciplinary Sciences

Discovery of DRP-104, a tumor-targeted metabolic inhibitor prodrug

Rana Rais et al.

Summary: 6-Diazo-5-oxo-l-norleucine (DON) is a glutamine antagonist that suppresses cancer cell metabolism while enhancing the metabolic fitness of tumor CD8+ T cells. The development of DON was halted due to dose-limiting gastrointestinal toxicities. In order to overcome this, a DON peptide prodrug, DRP-104, was designed and showed improved tolerability and enhanced efficacy in tumor regression. The effect of DRP-104 is dependent on CD8+ T cells and results in strong immunologic memory.

SCIENCE ADVANCES (2022)

Article Oncology

Targeting of Nrf2 improves antitumoral responses by human NK cells, TIL and CAR T cells during oxidative stress

Stefanie Renken et al.

Summary: Auranofin can significantly reduce intracellular ROS accumulation in human cytotoxic lymphocytes ex vivo, preserving their antitumoral activity and increasing resistance to oxidative stress.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

Review Cell Biology

NRF2 and Mitochondrial Function in Cancer and Cancer Stem Cells

Emiliano Panieri et al.

Summary: The NRF2-KEAP1 system regulates a wide range of transcriptional targets involved in redox homeostasis and cellular protection. NRF2 is a key driver of tumor progression and treatment resistance in cancer cells, making it a promising therapeutic target. Additionally, NRF2 has functional crosstalk with mitochondria, influencing mitochondrial homeostasis and cancer cell biology.
Article Oncology

A novel uterine leiomyoma subtype exhibits NRF2 activation and mutations in genes associated with neddylation of the Cullin 3-RING E3 ligase

Miika Mehine et al.

Summary: A novel subtype of uterine leiomyomas has been identified, characterized by distinct molecular features, mutations disrupting neddylation of the Cullin 3-RING E3 ligase, and activation of the NRF2 pathway. These findings provide new opportunities for targeted treatment of uterine leiomyomas.

ONCOGENESIS (2022)

Article Biochemistry & Molecular Biology

Exploring the target scope of KEAP1 E3 ligase-based PROTACs

Guangyan Du et al.

Summary: Targeted protein degradation (TPD) employs small molecules to recruit E3 ubiquitin ligases near the proteins of interest, leading to their degradation. In this study, we generated KEAP1-recruiting degraders using a KEAP1 inhibitor and successfully targeted BET family and FAK proteins. However, we found that KEAP1 had a narrow target scope as compared to CRBN-recruiting degraders. By linking the KEAP1-binding ligand to a CRBN-binding ligand, we developed a molecule that induced KEAP1 degradation but not CRBN degradation.

CELL CHEMICAL BIOLOGY (2022)

Article Multidisciplinary Sciences

Activation of the NRF2 antioxidant program sensitizes tumors to G6PD inhibition

Hongyu Ding et al.

Summary: The KEAP1/NRF2 pathway promotes metabolic rewiring to support redox homeostasis, and G6PD inhibition-induced TCA depletion is a therapeutic vulnerability of NRF2-activated cancer.

SCIENCE ADVANCES (2021)

Article Biology

Molecular basis for the disruption of Keap1-Nrf2 interaction via Hinge & Latch mechanism

Yuta Horie et al.

Summary: This study reveals that the dissociation of Keap1 from Nrf2, known as the Hinge-Latch mechanism, is triggered by Keap1-Nrf2 inhibitors and occurs during p62-mediated Nrf2 activation, rather than by electrophilic Nrf2 inducers. Insights gained from this research can be used for the development of Nrf2 activators targeting the Keap1-Nrf2 interaction.

COMMUNICATIONS BIOLOGY (2021)

Review Physiology

Cullin Deneddylation Suppresses the Necroptotic Pathway in Cardiomyocytes

Megan T. Lewno et al.

Summary: Cardiomyocyte death in the form of apoptosis and necrosis is a major cellular mechanism underlying cardiac pathogenesis, with recent research revealing that not all necrosis is accidental and there are multiple forms of regulated necrosis. Perturbation of Cullin deneddylation in cardiomyocytes impairs both the ubiquitin-proteasome system and the autophagic-lysosomal pathway.

FRONTIERS IN PHYSIOLOGY (2021)

Article Biochemistry & Molecular Biology

NRF2-Dependent Bioactivation of Mitomycin C as a Novel Strategy To Target KEAP1-NRF2 Pathway Activation in Human Cancer

Liam Baird et al.

Summary: Activating mutations in the KEAP1-NRF2 pathway are found in approximately 25% of lung tumors, leading to aggressive tumor growth, chemoresistance, and poor prognosis. The study identified mitomycin C as significantly more toxic in cells with aberrant Nrf2 activation, with NRF2 target genes responsible for the enhanced bioactivation. This suggests mitomycin C as a potential candidate for drug repositioning to target untreatable NRF2 activation in human tumors.

MOLECULAR AND CELLULAR BIOLOGY (2021)

Article Immunology

Redox regulation of immunometabolism

Jonathan Muri et al.

Summary: Immunometabolism research has revealed the significant impact of metabolic pathways and redox systems on immune cell functions, including the role of reactive oxygen species (ROS) and antioxidant pathways like thioredoxin and glutathione pathways. Studies show the central role of metabolism in determining the fate and function of immune cells, with cellular activation inducing profound changes in their oxidation-reduction system.

NATURE REVIEWS IMMUNOLOGY (2021)

Article Biochemistry & Molecular Biology

A small molecule G6PD inhibitor reveals immune dependence on pentose phosphate pathway

Jonathan M. Ghergurovich et al.

NATURE CHEMICAL BIOLOGY (2020)

Review Oncology

Oxidative Stress in Cancer

John D. Hayes et al.

CANCER CELL (2020)

Article Oncology

Keap1 mutation renders lung adenocarcinomas dependent on Slc33a1

Rodrigo Romero et al.

NATURE CANCER (2020)

Review Oncology

NRF2 Activation in Cancer: From DNA to Protein

Erica W. Cloer et al.

CANCER RESEARCH (2019)

Article Biochemistry & Molecular Biology

BACH1 Stabilization by Antioxidants Stimulates Lung Cancer Metastasis

Clotilde Wiel et al.

Article Cell Biology

Molecular Mechanism of Cellular Oxidative Stress Sensing by Keap1

Takafumi Suzuki et al.

CELL REPORTS (2019)

Article Biochemistry & Molecular Biology

Nrf2 and SQSTM1/p62 jointly contribute to mesenchymal transition and invasion in glioblastoma

Petri Polonen et al.

ONCOGENE (2019)

Article Multidisciplinary Sciences

Glutamine blockade induces divergent metabolic programs to overcome tumor immune evasion

Robert D. Leone et al.

SCIENCE (2019)

Review Biotechnology & Applied Microbiology

Therapeutic targeting of the NRF2 and KEAP 1 partnership in chronic diseases

Antonio Cuadrado et al.

NATURE REVIEWS DRUG DISCOVERY (2019)

Review Oncology

NRF2 and the Hallmarks of Cancer

Montserrat Rojo de la Vega et al.

CANCER CELL (2018)

Article Biochemistry & Molecular Biology

Oncogenic Signaling Pathways in The Cancer Genome Atlas

Francisco Sanchez-Vega et al.

Article Multidisciplinary Sciences

Nrf2 negatively regulates STING indicating a link between antiviral sensing and metabolic reprogramming

David Olagnier et al.

NATURE COMMUNICATIONS (2018)

Article Multidisciplinary Sciences

A catalogue of somatic NRF2 gain-of-function mutations in cancer

Michael John Kerins et al.

SCIENTIFIC REPORTS (2018)

Article Biochemistry & Molecular Biology

Halofuginone enhances the chemo-sensitivity of cancer cells by suppressing NRF2 accumulation

Kouhei Tsuchida et al.

FREE RADICAL BIOLOGY AND MEDICINE (2017)

Review Biochemistry & Molecular Biology

Stress-sensing mechanisms and the physiological roles of the Keap1-Nrf2 system during cellular stress

Takafumi Suzuki et al.

JOURNAL OF BIOLOGICAL CHEMISTRY (2017)

Article Biochemistry & Molecular Biology

Brusatol overcomes chemoresistance through inhibition of protein translation

Bryan Harder et al.

MOLECULAR CARCINOGENESIS (2017)

Article Biochemistry & Molecular Biology

Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis

Rodrigo Romero et al.

NATURE MEDICINE (2017)

Article Biochemical Research Methods

Application of Mass Spectrometry Profiling to Establish Brusatol as an Inhibitor of Global Protein Synthesis

Steffan Vartanian et al.

MOLECULAR & CELLULAR PROTEOMICS (2016)

Article Biochemistry & Molecular Biology

Characterizations of Three Major Cysteine Sensors of Keap1 in Stress Response

Ryota Saito et al.

MOLECULAR AND CELLULAR BIOLOGY (2016)

Article Biochemistry & Molecular Biology

The Mediator Subunit MED16 Transduces NRF2-Activating Signals into Antioxidant Gene Expression

Hiroki Sekine et al.

MOLECULAR AND CELLULAR BIOLOGY (2016)

Article Biochemistry & Molecular Biology

Small Molecule Inhibitor of NRF2 Selectively Intervenes Therapeutic Resistance in KEAP1-Deficient NSCLC Tumors

Anju Singh et al.

ACS CHEMICAL BIOLOGY (2016)

Article Cell Biology

NRF2 activation by antioxidant antidiabetic agents accelerates tumor metastasis

Hui Wang et al.

SCIENCE TRANSLATIONAL MEDICINE (2016)

Article Multidisciplinary Sciences

Nrf2 suppresses macrophage inflammatory response by blocking proinflammatory cytokine transcription

Eri H. Kobayashi et al.

NATURE COMMUNICATIONS (2016)

Article Biochemistry & Molecular Biology

A Small Molecule Inhibits Deregulated NRF2 Transcriptional Activity in Cancer

Michael J. Bollong et al.

ACS CHEMICAL BIOLOGY (2015)

Review Cell Biology

Protein neddylation: beyond cullin-RING ligases

Radoslav I. Enchev et al.

NATURE REVIEWS MOLECULAR CELL BIOLOGY (2015)

Article Oncology

Oncogenic KRAS Confers Chemoresistance by Upregulating NRF2

Shasha Tao et al.

CANCER RESEARCH (2014)

Article Biochemistry & Molecular Biology

Structural Basis for Cul3 Protein Assembly with the BTB-Kelch Family of E3 Ubiquitin Ligases

Peter Canning et al.

JOURNAL OF BIOLOGICAL CHEMISTRY (2013)

Article Medicine, Research & Experimental

Transcription factor NRF2 regulates miR-1 and miR-206 to drive tumorigenesis

Anju Singh et al.

JOURNAL OF CLINICAL INVESTIGATION (2013)

Article Biochemistry & Molecular Biology

Phosphorylation of p62 Activates the Keap1-Nrf2 Pathway during Selective Autophagy

Yoshinobu Ichimura et al.

MOLECULAR CELL (2013)

Article Multidisciplinary Sciences

Regulatory flexibility in the Nrf2-mediated stress response is conferred by conformational cycling of the Keap1-Nrf2 protein complex

Liam Baird et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)

Review Biochemistry & Molecular Biology

The Keap1-Nrf2 pathway: Mechanisms of activation and dysregulation in cancer

Emilia Kansanen et al.

REDOX BIOLOGY (2013)

Article Mathematical & Computational Biology

Analysis of dimerization of BTB-IVR domains of Keap1 and its interaction with Cul3, by molecular modeling

Nandini Chauhan et al.

BIOINFORMATION (2013)

Article Biochemistry & Molecular Biology

Structural and Functional Characterization of Nrf2 Degradation by the Glycogen Synthase Kinase 3/β-TrCP Axis

Patricia Rada et al.

MOLECULAR AND CELLULAR BIOLOGY (2012)

Article Multidisciplinary Sciences

Keap1 degradation by autophagy for the maintenance of redox homeostasis

Keiko Taguchi et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)

Review Oncology

NRF2 and cancer: the good, the bad and the importance of context

Michael B. Sporn et al.

NATURE REVIEWS CANCER (2012)

Article Biochemistry & Molecular Biology

Frequent epigenetics inactivation of KEAP1 gene in non-small cell lung cancer

Lucia Anna Muscarella et al.

EPIGENETICS (2011)

Article Biochemistry & Molecular Biology

Electrophilic Nitro-fatty Acids Activate NRF2 by a KEAP1 Cysteine 151-independent Mechanism

Emilia Kansanen et al.

JOURNAL OF BIOLOGICAL CHEMISTRY (2011)

Article Multidisciplinary Sciences

Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis

Gina M. De Nicola et al.

NATURE (2011)

Article Multidisciplinary Sciences

Brusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediated defense mechanism

Dongmei Ren et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)

Review Biochemistry & Molecular Biology

Regulation of the Nrf2-Keap1 Antioxidant Response by the Ubiquitin Proteasome System: An Insight into Cullin-Ring Ubiquitin Ligases

Nicole F. Villeneuve et al.

ANTIOXIDANTS & REDOX SIGNALING (2010)

Article Biochemistry & Molecular Biology

A Noncanonical Mechanism of Nrf2 Activation by Autophagy Deficiency: Direct Interaction between Keap1 and p62

Alexandria Lau et al.

MOLECULAR AND CELLULAR BIOLOGY (2010)

Article Biochemistry & Molecular Biology

Direct Interaction between Nrf2 and p21Cip1/WAF1 Upregulates the Nrf2-Mediated Antioxidant Response

Weimin Chen et al.

MOLECULAR CELL (2009)

Article Multidisciplinary Sciences

An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer

Teresa A. Soucy et al.

NATURE (2009)

Article Biochemistry & Molecular Biology

Hypermethylation of the Keap1 gene in human lung cancer cell lines and lung cancer tissues

Rui Wang et al.

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2008)

Article Cell Biology

The Cullin3 ubiquitin ligase functions as a Nedd8-bound heterodimer

Wananit Wimuttisuk et al.

MOLECULAR BIOLOGY OF THE CELL (2007)

Article Biochemistry & Molecular Biology

Keap1 recruits Neh2 through binding to ETGE and DLG motifs: Characterization of the two-site molecular recognition model

KI Tong et al.

MOLECULAR AND CELLULAR BIOLOGY (2006)

Article Biochemistry & Molecular Biology

Structural basis for defects of Keap1 activity provoked by its point mutations in lung cancer

B Padmanabhan et al.

MOLECULAR CELL (2006)

Article Biochemistry & Molecular Biology

CAND1-mediated substrate adaptor recycling is required for efficient repression of Nrf2 by Keap1

SC Lo et al.

MOLECULAR AND CELLULAR BIOLOGY (2006)

Article Biochemistry & Molecular Biology

BTB protein keap1 targets antioxidant transcription factor nrf2 for ubiquitination by the cullin 3-Roc1 ligase

M Furukawa et al.

MOLECULAR AND CELLULAR BIOLOGY (2005)

Article Biochemistry & Molecular Biology

BTB/POZ domain proteins are putative substrate adaptors for cullin 3 ubiquitin ligases

R Geyer et al.

MOLECULAR CELL (2003)

Article Biochemistry & Molecular Biology

Electrophile response element-mediated induction of the cystine/glutamate exchange transporter gene expression

H Sasaki et al.

JOURNAL OF BIOLOGICAL CHEMISTRY (2002)